Oramed Pharmaceuticals Inc.

Director's Dealing • Sep 18, 2019

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Gabay		2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									(Check all applicable) Director		5. Relationship of Reporting Person(s) to Issuer 10% Owner
(Last)		(First) (Middle) HI-TECH PARK 2/4 GIVAT-RAM		3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019									Officer (give title		Other (specify below) CFO, Treasurer and Secretary
	P.O. BOX 39098										4. If Amendment, Date of Original Filed (Month/Day/Year)		Line)	6. Individual or Joint/Group Filing (Check Applicable
(Street) JERUSALEM	L3		91390											X Person			Form filed by One Reporting Person Form filed by More than One Reporting
(City)		(State)	(Zip)
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)						2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. and 5) 8)				5. Amount of Securities Beneficially Owned	(D) or (Instr. 4)		6. Ownership Form: Direct Indirect (I)	7. Nature of Indirect Beneficial Ownership
					Code	V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
											Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Price of (Month/Day/Year) Derivative Security				4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code		V (A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Stock Option (right to buy)	\$3.55	06/17/2019			(1) D			33,146	(1)		06/17/2029	Common Stock	33,146	\$0	0		D
Stock

Explanation of Responses:

Option (right to buy)

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022.

(1) 33,146 (1) 09/12/2029

/s/ Avraham Gabay 09/12/2019

Common Stock

** Signature of Reporting Person Date

33,146 \$0 33,146 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\$3.55 09/12/2019 A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

T

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person KIDRON NADAV						ORMP ]	ORAMED		2. Issuer Name and Ticker or Trading Symbol PHARMACEUTICALS			[ X	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director		X	10% Owner
(Last) (First) (Middle) 142 W. 57TH ST.							09/12/2019		3. Date of Earliest Transaction (Month/Day/Year)			X	Officer (give title Other (specify below) below) President and CEO
(Street) NEW YORK NY 10019 (City) (State) (Zip)									4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) X	6. Individual or Joint/Group Filing (Check Applicable Person			Form filed by One Reporting Person Form filed by More than One Reporting
														Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
	1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)						2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. and 5) 8)				5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	V	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)
									(e.g., puts, calls, warrants, options, convertible securities)					Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of 2. 3. Transaction 3A. Deemed Derivative Security Conversion Date Execution Date, if (Instr. 3) or Exercise (Month/Day/Year) any Price of (Month/Day/Year) Derivative Security					8)	4. Transaction 5. Number of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) V (A) (D)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned		10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code			Date Exercisable	Date	Expiration Title		Amount or Number of Shares	Following Reported Transaction(s) (Instr. 4)		(I) (Instr. 4)
Stock Option (right to buy)	\$3.16	02/26/2019			(1) D			196,500	(1)		02/26/2029		Common Stock	196,500	\$0	0		D

Explanation of Responses:

Stock Option (right to buy)

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

(1) 196,500 (1) 09/12/2029

/s/ Nadav Kidron 09/12/2019

Common Stock

196,500 \$0 196,500 D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\$3.16 09/12/2019 A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Kidron Miriam						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director
(Last) (First) (Middle) 2 ELZA STREET							ORMP ] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019									Officer (give title		10% Owner below) Chief Scientific Officer	Other (specify
(Street) JERUSALEM L3 93706 (City) (State) (Zip)									4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) X	6. Individual or Joint/Group Filing (Check Applicable Person			Form filed by One Reporting Person Form filed by More than One Reporting
														Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. and 5) 8)				5. Amount of Securities Beneficially Owned		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership
									Code	V	Amount	(A) or (D)		Price	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
									(e.g., puts, calls, warrants, options, convertible securities)					Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Derivative Security (Instr. 3)	2. or Exercise Price of Derivative Security	3. Transaction 3A. Deemed Conversion Date (Month/Day/Year) any		Execution Date, if 8) (Month/Day/Year)		4. Transaction 5. Number of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	V	(A)	(D)	Date Exercisable	Date	Expiration	Title		Amount or Number of Shares			Reported Transaction(s) (Instr. 4)

Explanation of Responses:

Stock Option (right to buy)

Stock Option (right to buy)

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

(1) 104,000 (1) 02/26/2029

(1) 104,000 (1) 09/12/2029

/s/ Miriam Kidron 09/12/2019

Common Stock

Common Stock

104,000 \$0 0 D

104,000 \$0 104,000 D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\$3.16 02/26/2019 D

\$3.16 09/12/2019 A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person RAKIN KEVIN	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last) (First) (Middle) 36 CHURCH LANE	3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019	Officer (give title Other (specify below) below)
(Street) WESTPORT CT 06880 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code	V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code		V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Stock Option (right to buy)	\$4.17	04/10/2019		(1) D				10,000 12/31/2019 04/10/2029		Common Stock	10,000	\$0	0	D
Stock Option (right to buy)	\$4.17	09/12/2019		(1) A		10,000			12/31/2019 09/12/2029	Common Stock	10,000	\$0	10,000	D

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option.

/s/ Kevin Rakin 09/12/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Hexter Joshua		*	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
			ORMP ]		Director	10% Owner
(Last) 9 ALFASI	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019	X	Officer (give title below) Chf. Op. & Bus. Officer	Other (specify below)
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
JERUSALEM	L3 92302			X	Form filed by One Reporting Person Form filed by More than One Reporting
(City)	(State)	(Zip)			Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code	V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)	6. Date Exercisable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code		V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$3.69	09/12/2019		A		100,000		(1)	09/12/2029	Common Stock	100,000	\$0	100,000	D

Explanation of Responses:

1. The Stock Options will vest in 16 equal installments of 6,250 on the first day of every three month period beginning November 1, 2019.

/s/ Joshua Hexter 09/12/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.